Markey Cancer Center

Cancer, COVID and the Kentucky Economy: How 'Sweet Annie' Could Make an Impact

Aug 11, 2020, 8:19 AM

Artemisia annua or "Sweet Annie" has been used as a medicinal herb for centuries. With potential to treat a variety of cancers & even COVID-19, this plant is more relevant than ever & UK is showing how we can take it from Kentucky fields to the lab to our patients.

Kuhs Named Co-Leader of Markey Cancer Prevention & Control Research Program

Aug 4, 2020, 8:21 AM

As a cancer prevention researcher trained in both basic laboratory science and epidemiology, Kuhs’ experience allows her to apply basic science findings to population-based studies, which will be essential to lowering cancer rates in the hardest-hit areas of the state.

UK Study Provides New Insight on Colorectal Cancer Growth

Jul 14, 2020, 8:40 AM

A group led by the Markey Cancer Center researcher Qing-Bai She discovered that SMS is overexpressed in colorectal cancers and plays an important role in balancing cellular spermidine levels that are a necessary adaptation for colorectal cancer growth.

Artemisia Annua Could Be Promising Treatment for COVID-19

Jun 25, 2020, 8:07 AM

The new potential treatment has been added to the University of Kentucky’s innovative clinical trial for experimental COVID-19 therapies, which was launched by leaders from UK’s Markey Cancer Center, College of Medicine and College of Pharmacy in May.

UK, ArtemiLife Partner to Test for Anti-Cancer Activity of Artemisia Annua Extracts

Jun 3, 2020, 8:28 AM

UK and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.

UK Launches Clinical Trial to Evaluate Novel Treatments for COVID-19

May 7, 2020, 8:21 AM

“We are pleased to be able to offer this clinical trial to patients with COVID-19 in Kentucky. While there is no standard treatment for COVID-19, this trial gives us the ability to test multiple therapies rapidly in order to identify the most promising agents.”